Skip to main content

Advertisement

SpringerLink
Log in

A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145

  • Phase II Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Multiple myeloma is a disease in which angiogenesis is postulated to be a target for therapy. Based on this hypothesis, we conducted a phase II trial of ZD6474 (Zactima™; a VEGFR inhibitor) 100 mg p.o. daily in patients with relapsed multiple myeloma. The primary efficacy endpoint was objective response as assessed by reduction in M protein. There were 18 patients with a mean age of 64 years. One patient was ineligible and one was not evaluable. Overall, ZD6474 was well tolerated and pharmacokinetic testing demonstrated that adequate drug levels were achieved. The most common drug-related adverse events were nausea, vomiting, fatigue, rash, pruritis, headache, diarrhea, dizziness, and sensory neuropathy, all of which were Grade I–II in severity. There were no drug-related serious adverse events. Laboratory adverse events were infrequent: one patient had Grade III anemia, and there were no Grade III changes in biochemistry. No significant QTc interval changes were seen. There were no responses in M protein levels. In conclusion, ZD6474 was well tolerated at a dose of 100 mg per day and achieved plasma levels predicted to inhibit VEGF signaling. However, this was not reflected in clinical benefit since none of the patients had a reduction in M protein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Riedel DA, Pottern LM (1992) The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 6:225–247

    PubMed  CAS  Google Scholar 

  2. Bergsagel DE (1995) The role of chemotherapy in the treatment of multiple myeloma. Baillieres Clin Haematol 8:783–794

    PubMed  CAS  Google Scholar 

  3. Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, Seaman JJ (1997) Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 37:285–290

    PubMed  CAS  Google Scholar 

  4. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334:488–493

    Article  PubMed  CAS  Google Scholar 

  5. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571

    Article  PubMed  CAS  Google Scholar 

  6. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617

    Article  PubMed  CAS  Google Scholar 

  7. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91–97

    Article  PubMed  CAS  Google Scholar 

  8. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495–2502

    Article  PubMed  CAS  Google Scholar 

  9. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883

    Article  PubMed  CAS  Google Scholar 

  10. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F (1999) Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93:3064–3073

    PubMed  CAS  Google Scholar 

  11. Vacca A, Di Loreto M, Ribatti D, Di Stefano R, Gadaleta-Caldarola G, Iodice G, Caloro D, Dammacco F (1995) Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol 50:9–14

    PubMed  CAS  Google Scholar 

  12. Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B (1999) Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 10:65–70

    PubMed  CAS  Google Scholar 

  13. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645–4655

    PubMed  CAS  Google Scholar 

  14. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR (2003) Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89:1889–1895

    Article  PubMed  CAS  Google Scholar 

  15. Hurwitz HI, Holden SN, Eckhard SC, Rosenthal M, de Boer R, Rischin D, Green M, Basser R (2002) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling in patients with solid tumors. Proc AM Soc Clinical Oncol 21

  16. Minami H, Ebi H, Tahara M, Sasaki Y, Yamamoto N, Yamada Y, Tamura T, Saijo N (2002) A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc AM Soc Clinical Oncol 21:82a

    Google Scholar 

  17. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143–151

    Article  PubMed  CAS  Google Scholar 

  18. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492–494

    Article  PubMed  CAS  Google Scholar 

  19. Neben K, Moehler T, Kraemer A, Benner A, Egerer G, Ho AD, Goldschmidt H (2001) Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 115:605–608

    Article  PubMed  CAS  Google Scholar 

  20. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943–2950

    PubMed  CAS  Google Scholar 

  21. Dredge K, Marriott JB, Dalgleish AG (2002) Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol 22:425–437

    PubMed  CAS  Google Scholar 

  22. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210–216

    Article  PubMed  CAS  Google Scholar 

  23. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:1950–1961

    PubMed  CAS  Google Scholar 

  24. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99:4525–4530

    Article  PubMed  CAS  Google Scholar 

  25. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ (2004) Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 10:88–95

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NCIC Clinical Trials Group, Kingston, Ontario, Canada

    Michael J. Kovacs, Donna E. Reece, Deborah Marcellus, Ralph M. Meyer, Sarah Mathews & Elizabeth Eisenhauer

  2. Previously at AstraZeneca, Wilmington, Delaware, USA

    Rui-Ping Dong

  3. London Health Sciences Centre, Room A2–401, VC, 800 Commissioners Road East, London, ON, N6A 4G5

    Michael J. Kovacs

Authors
  1. Michael J. Kovacs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donna E. Reece
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deborah Marcellus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ralph M. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sarah Mathews
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rui-Ping Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elizabeth Eisenhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael J. Kovacs.

Additional information

Zactima is a trademark of the AstraZeneca group of companies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kovacs, M.J., Reece, D.E., Marcellus, D. et al. A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145. Invest New Drugs 24, 529–535 (2006). https://doi.org/10.1007/s10637-006-9022-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-006-9022-7

Keywords

Search

Navigation